This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Sarah J. Singer, RPh; Toni D. Piazza-Hepp, PharmD; Luigi S. Girardi, MD; Nasim R. Moledina, MD
Food and Drug Administration Rockville, Md

JAMA. 1997;277(4):295-296.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Minocycline hydrochloride is a semisynthetic derivative of tetracyline. Although approved by the US Food and Drug Administration (FDA) for the treatment of infections caused by a variety of microorganisms,¹ recent data indicate that from 1990 through July 1996, approximately 65% of oral minocycline use in the United States was for treatment of acne.²

In a recent article, Gough and colleagues³ described cases of autoimmune hepatitis, systemic lupus erythematosus, or both associated with the use of minocycline in the United Kingdom. Lupuslike symptoms and autoimmune hepatitis in association with minocycline use in US patients have not been described in the literature. However, US product labeling for minocycline lists "hepatitis," "exacerbation of systemic lupus erythematosus," and "[a] transient lupus-like syndrome" as possible adverse reactions.¹

From 1972 through February 1996, the FDA's MEDWatch Reporting Program had received only 1 report of a case resembling the autoimmune . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?